About GondolaBio

HOW WE GOT HERE

Founded in 2024 as a spinout of BridgeBio Pharma, GondolaBio is backed by $300M in private financing from external investors to develop next-generation therapeutics for patients living with genetic diseases.

OUR GOAL

 GondolaBio aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, modalities, and stages ranging from early discovery to clinical development.